Common ICI combinations include nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor), used for melanoma, renal cell carcinoma, and non-small cell lung cancer. Here, PDCD1 is linked to hereditary clear cell renal cell carcinoma.